Table 1 Baseline tumour pathology and treatment characteristics
Total patients n = 87 n (%) | |||||
|---|---|---|---|---|---|
cT stage | T1 | T2 | T3 | T4 | |
1 (1.1%) | 53 (60.9%) | 18 (20.7%) | 15 (17.2%) | ||
cN stage | N1 | N2 | N3 | ||
76 (86%) | 7 (9%) | 4 (5%) | |||
Type of chemotherapy | Anthracycline only | Taxane only | Combination | ||
14 (16.1%) | 5 (5.7%) | 68 (78.2%) | |||
Trastuzumab | Trastuzumab | ||||
34 (39.1%) | |||||
Type of surgery | Breast conservation | Mastectomy | |||
29 (33.3%) | 58 (66.7%) | ||||
Tumour grade | G1 | G2 | G3 | ||
1 (1.1%) | 23 (26.4%) | 63 (72.4%) | |||
Tumour type | Invasive ductal | Invasive lobular | Other | ||
79 (90.8%) | 4 (4.6%) | 4 (4.6%) | |||
Immunophenotype | ER +/HER2 + | ER +/HER2 | ER −/HER2 | ER −/HER2 – | |
26 (29.9%) | 30 (34.5%) | 8 (9.2%) | 23 (26.4%) | ||
Pathological response of tumour | Complete response | Near complete | Partial response | Minimal response | No response |
15 (17.2%) | 21 (24.1%) | 41 (47.1%) | 2 (2.3%) | 8 (9.2%) | |
Pathological assessment of nodes | No residual metastasis | ITC/ Mic only | 1–2 nodes with macrometasis | More than 2 nodes with metastasis | |
23 (26.4%) | 10 (11.5%) | 28 (32.3%) | 26 (29.9%) | ||